Abstract

This statement sets out advice from the JCVI on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression around the time of their first or second vaccine doses.

  • Recommendation
  • Europe
  • United Kingdom
  • immunocompromised
  • COVID-19